E Jacobs1,2, W Rathmann1,2, T Tönnies1, D Arendt3, M Marchowez3, L Veith3, O Kuss1,2,4, R Brinks1,5, A Hoyer1. 1. Institute for Biometrics and Epidemiology, German Diabetes Centre, Leibniz Centre for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. 2. German Centre for Diabetes Research, München-Neuherberg, Germany. 3. Department of Statistics, Ludwig-Maximilians-Universität München, München, Germany. 4. Institute of Medical Statistics, Düsseldorf University Hospital and Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. 5. and, Hiller Research Unit for Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Abstract
AIM: For many European countries, including Germany, no valid estimates are available on age at diagnosis of Type 2 diabetes. Thus, we aimed to estimate the age at diagnosis in Germany. METHODS: Age at diagnosis of Type 2 diabetes in Germany was estimated based on Type 2 diabetes prevalence and incidence and the age distribution of the German population. Age- and sex-specific incidence and prevalence in 2014/2015, based on claims data from statutory health insurance (n= 69 000 000, ~85% of the German population), and the age pyramid for Germany in 2015 were used for the calculation. Age at Type 2 diabetes diagnosis was stratified by sex. CIs were estimated using bootstrap methods. In addition, the age range in which 50% of the population received a diagnosis of Type 2 diabetes was calculated (the interquartile range). RESULTS: The mean ± sd age at Type 2 diabetes diagnosis in 2015 was 61.0 ± 13.4 years (95% CI 60.9-61.0) in men. Women were diagnosed ~2 years later than men (mean age 63.4 ± 14.9 years; 95% CI 63.4-63.5). The age range in which 50% of the population was diagnosed with diabetes was 53-72 years for men and 54-76 years for women. CONCLUSIONS: The sex differences are mainly attributable to a higher incidence of Type 2 diabetes in men than women during middle age and the higher absolute number of women in the older ages. The early age at diabetes diagnosis compared to average life expectancy means that the risk of diabetes-related complications is increased.
AIM: For many European countries, including Germany, no valid estimates are available on age at diagnosis of Type 2 diabetes. Thus, we aimed to estimate the age at diagnosis in Germany. METHODS: Age at diagnosis of Type 2 diabetes in Germany was estimated based on Type 2 diabetes prevalence and incidence and the age distribution of the German population. Age- and sex-specific incidence and prevalence in 2014/2015, based on claims data from statutory health insurance (n= 69 000 000, ~85% of the German population), and the age pyramid for Germany in 2015 were used for the calculation. Age at Type 2 diabetes diagnosis was stratified by sex. CIs were estimated using bootstrap methods. In addition, the age range in which 50% of the population received a diagnosis of Type 2 diabetes was calculated (the interquartile range). RESULTS: The mean ± sd age at Type 2 diabetes diagnosis in 2015 was 61.0 ± 13.4 years (95% CI 60.9-61.0) in men. Women were diagnosed ~2 years later than men (mean age 63.4 ± 14.9 years; 95% CI 63.4-63.5). The age range in which 50% of the population was diagnosed with diabetes was 53-72 years for men and 54-76 years for women. CONCLUSIONS: The sex differences are mainly attributable to a higher incidence of Type 2 diabetes in men than women during middle age and the higher absolute number of women in the older ages. The early age at diabetes diagnosis compared to average life expectancy means that the risk of diabetes-related complications is increased.
Authors: Franziska Püschner; Sarah Wetzel; Dominika Urbanski-Rini; Nick Bertram; Monika Schliffke; Martin Göhl; Carsten Petersen Journal: Qual Life Res Date: 2021-05-19 Impact factor: 4.147
Authors: Stephanie Linder; Karim Abu-Omar; Wolfgang Geidl; Sven Messing; Mustafa Sarshar; Anne K Reimers; Heiko Ziemainz Journal: PLoS One Date: 2021-02-09 Impact factor: 3.240
Authors: Jon J Rasmussen; Christian Selmer; Signe Frøssing; Morten Schou; Jens Faber; Christian Torp-Pedersen; Gunnar H Gislason; Lars Køber; David M Hougaard; Arieh S Cohen; Caroline Kistorp Journal: J Endocr Soc Date: 2020-05-05